Search Results - "Riesco, M. C."

The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications by Soldevilla, B., Carretero-Puche, C., Gomez-Lopez, G., Al-Shahrour, F., Riesco, M.C., Gil-Calderon, B., Alvarez-Vallina, L., Espinosa-Olarte, P., Gomez-Esteves, G., Rubio-Cuesta, B., Sarmentero, J., La Salvia, A., Garcia-Carbonero, R.

“…Solid tumour growth is the consequence of a complex interplay between cancer cells and their microenvironment. Recently, a new global transcriptomic immune…”
Get full text

A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients by Toledano-Fonseca, M., Gómez-España, M.A., Élez, E., Grávalos, C., García-Alfonso, P., Rodríguez, R., Losa, F., Alés Díaz, I., Graña, B., Valladares-Ayerbes, M., García-Ortiz, M.V., Polo, E., Salgado, M., Rivera, F., Safont, M.J., Salud, A., Ruiz-Casado, A., Tabernero, J.M., Riesco, M.C., Rodríguez-Ariza, A., Aranda, E.

“…The benefit of adding the antiangiogenic drug aflibercept to FOLFIRI regime in metastatic colorectal cancer (CRC) patients resistant to or progressive on an…”
Get full text

Development and internal validation of a predictive nomogram of progression-free survival in well-differentiated stage IV gastroenteropancreatic neuroendocrine tumours treated with somatostatin analogues: GETNE-TRASGU study by Garcia-Carbonero, R., Alonso, V., Capdevila, J., Sanchez Canovas, M., Alonso, T., Benavent, M., Custodio, A., Crespo Herrero, G., Lopez, C., Hernando, J., Riesco Martinez, M.C., Escudero, P., Gallego Plazas, J., Marazuela, M., Diaz, J.A., Llanos-Munoz, M., La Casta, A., Percovich, J.C., Jimenez-Fonseca, P., Carmona-Bayonas, A.

Get full text

Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer by Hidalgo, M., Bazan-Peregrino, M., Laquente, B., Gallego, R Alvarez, Mato-Berciano, A., Giménez-Alejandre, M., Maliandi, V., Martinez, M C Riesco, Moreno, R., Morell, M., Perez-Carreras, M., Gornals, J., Prados, S., Capella, G., Alemany, R., Salazar, R., Blasi, E., Blasco, C., Cascallo, M., Garcia-Carbonero, R.

Get full text

459PProof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer by Hidalgo, M, Bazan-Peregrino, M, Laquente, B, Gallego, R Alvarez, Mato-Berciano, A, Giménez-Alejandre, M, Maliandi, V, Martinez, M C Riesco, Moreno, R, Morell, M, Perez-Carreras, M, Gornals, J, Prados, S, Capella, G, Alemany, R, Salazar, R, Blasi, E, Blasco, C, Cascallo, M, Garcia-Carbonero, R

“…Abstract Background Dense stroma is a hallmark of hard-to-treat cancers such as pancreatic adenocarcinoma. VCN-01 oncolytic adenovirus is designed to replicate…”
Get full text

459P - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer by Hidalgo, M., Bazan-Peregrino, M., Laquente, B., Gallego, R Alvarez, Mato-Berciano, A., Giménez-Alejandre, M., Maliandi, V., Martinez, M C Riesco, Moreno, R., Morell, M., Perez-Carreras, M., Gornals, J., Prados, S., Capella, G., Alemany, R., Salazar, R., Blasi, E., Blasco, C., Cascallo, M., Garcia-Carbonero, R.

“…Dense stroma is a hallmark of hard-to-treat cancers such as pancreatic adenocarcinoma. VCN-01 oncolytic adenovirus is designed to replicate in cancer cells…”
Get full text

Final results of a risk-adapted policy of adjuvant chemotherapy (ACT) in patients with invasive bladder carcinoma (IBC) by Arranz Arija, J. A., Jerez Gilarranz, Y., Soria Lovelle, A., López López, C., Sabin Dominguez, P., Riesco, M. C., Adeva Alfonso, J., Urosa Velasco, D., López Juárez, E., González Beca, R., Martin, M.

“…Abstract only…”
Get full text

518PSILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus by De Jesus-Acosta, A, Crespo Herrero, G, Gómez-Dorronsoro, M L, Alonso, V, Riesco Martinez, M C, Custodio, A, Lopez, C, Benavent, M, Carmona Bayonas, A, Jimenez-Fonseca, P, Llanos, M, López De San Vicente, B, Arrazubi Arrula, V, Grandez, R, González-Borja, I, Goñi, S, Arozarena, I, Baretti, M, Viudez, A

“…Abstract Background Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as…”
Get full text

710PSystemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: First-in-human clinical trial by Garcia-Carbonero, R, Gil Martín, M, Alvarez Gallego, R, Macarulla Mercade, T, Riesco Martinez, M C, Guillen-Ponce, C, Vidal, N, Real, F X, Moreno, R, Maliandi, V, Mato-Berciano, A, Bazan-Peregrino, M, Capella, G, Alemany, R, Blasi, E, Blasco, C, Cascallo, M, Salazar, R

“…Abstract Background Expression of hyaluronidase from the selective oncolytic adenovirus VCN-01 modifies tumor matrix in pancreatic tumours. Such effect…”
Get full text

The role of antiangiogenic therapy in advanced gastro-esophageal cancer: a systematic review and meta-analysis by Riesco-Martinez, M.C., Díaz-Serrano, A., Gomez-Martin, C., Alfonso, J. Adeva, Cabrera, E. Sabater, Garcia-Carbonero, R.

Get full text

1315PDevelopment and internal validation of a predictive nomogram of progression-free survival in well-differentiated stage IV gastroenteropancreatic neuroendocrine tumours treated with somatostatin analogues: GETNE-TRASGU study by Garcia-Carbonero, R, Alonso, V, Capdevila, J, Sanchez Canovas, M, Alonso, T, Benavent, M, Custodio, A, Crespo Herrero, G, Lopez, C, Hernando, J, Riesco Martinez, M C, Escudero, P, Gallego Plazas, J, Marazuela, M, Diaz, J A, Llanos-Munoz, M, La Casta, A, Percovich, J C, Jimenez-Fonseca, P, Carmona-Bayonas, A

Get full text

Abstract P1-14-05: Is there a correlation between androgen receptor (AR) expression in metastatic breast cancer (MBC) ER+/Her2- and response to anti-estrogen treatment? by Riesco Martínez, MC, Hanna, W, Ghorab, Z, Warner, E

“…Background: AR expression varies significantly according to molecular breast cancer phenotype, being more common in Luminal A and B tumors where it is found in…”
Get full text

Prognostic relevance of Src activation in stage II-III colon cancer by Perez, Julia Martinez, MD, Lopez-Calderero, Iker, MD, Saez, Carmen, PhD, Benavent, Marta, MD, Limon, Maria L., MD, Gonzalez-Exposito, Reyes, MD, Soldevilla, B., PhD, Riesco-Martinez, Maria C., MD, Salamanca, Javier, MD, Carnero, Amancio, PhD, Garcia-Carbonero, Rocio, MD, PhD

“…Src belongs to a family of cytoplasmic tyrosine kinases that play a key role in tumor initiation and progression. Src activation has been associated with a…”
Get full text